SteelPeak Wealth’s TG Therapeutics TGTX Stock Holding History

SteelPeak Wealth’s Portfolio TGTX Stock Details TGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$326K	Buy	+5,933	New	+$243K	0.01%	506
2025 Q4	–	Sell	-5,900	Closed	-$213K	–	647
2025 Q3	$213K	Hold	5,900	–	–	0.01%	528
2025 Q2	$212K	Hold	5,900	–	–	0.01%	491
2025 Q1	$233K	Buy	+5,900	New	+$199K	0.01%	465

Other funds holding TGTX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

CAM

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

SteelPeak Wealth's TGTX Position: Q2 2026 in Review

SteelPeak Wealth opened a new position in TG Therapeutics (TGTX) in Q2 2026: 5,933 shares worth $326K. The stake represents 0.01% of the portfolio and ranks #506 among its holdings. This is a return to the name: SteelPeak Wealth previously reported a position in TGTX as recently as Q3 2025.

SteelPeak Wealth first reported a position in TGTX in Q1 2025 and has held it in 4 quarters since. 427 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

SteelPeak Wealth held 5,933 shares of TG Therapeutics worth $326K as of Q2 2026.
TG Therapeutics was a new SteelPeak Wealth position in Q2 2026.
TG Therapeutics made up 0.01% of SteelPeak Wealth's portfolio in Q2 2026, its #506 holding.
SteelPeak Wealth first reported a position in TG Therapeutics in Q1 2025 and has held it in 4 quarters since.
427 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on SteelPeak Wealth's 13F filing for Q2 2026, filed 13 Jul 2026.